Introduction
============

Pancreatic cancer has extremely poor prognosis and is the fourth leading cause of cancer-related death ([@B18]; [@B24]; [@B46]). Pancreatic ductal adenocarcinoma (PDAC) comprises more than 85% of all pancreatic cancer and has an overall 5-year survival rate of less than 5% ([@B18]). A major challenge in the clinics is the lack of effective methods for early detection and treatment. Three types of "preneoplastic" lesions have been characterized as potential precursors of PDAC, including pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms (MCN) ([@B21]; [@B33]). In particular, PanINs represent the majority of early neoplastic lesions and are characterized by three morphologically defined stages, namely PanIN1, 2, and 3 ([@B21]; [@B33]). However, the signaling events involved in promoting the transition from the preneoplastic lesion to the more advanced and aggressive forms are still not fully understood.

Recepteur d'origine nantais (RON), also known as macrophage stimulating 1-receptor or MST1R) is a c-MET family receptor tyrosine kinase ([@B39]; [@B42]). Ligand-dependent or independent activation of RON leads to cell proliferation, migration, and matrix invasion ([@B31]; [@B51]). Aberrant activation of RON has been linked to various forms of human cancers. For example, overexpression of RON is found in the majority of primary human colorectal adenocarcinoma and colon cancer cell lines ([@B12]; [@B56]). In addition, elevation of RON expression has also been found in bladder, head and neck squamous cell carcinomas, breast and ovarian cancers ([@B32]; [@B28]; [@B13]; [@B27]; [@B53]). The ligand for RON, known as the macrophage-stimulating protein (MSP) or the hepatocyte growth factor-like protein (HGFL), is a member of the plasminogen-prothrombin family proteins ([@B52]; [@B9]; [@B55]). MSP is expressed as an inactive precursor and becomes activated upon proteolytic cleavage by type II membrane serine proteases, such as matriptase (also known as ST-14) ([@B7]).

Here, we show that elements of the MSP-RON signaling pathway are upregulated in pancreatic cancer cells as well as in cancer-associated pancreatic stellate cells (PSCs). Our results support the notion that activation of MSP-RON signaling represents a hallmark event in progression of PDAC.

Results
=======

MSP Is Upregulated in Human PDAC
--------------------------------

We examined the expression patterns of MSP in normal human pancreatic tissues and in PDAC by immunohistochemistry (IHC). Our results show that, while MSP expression is minimal in normal pancreas, it is significantly upregulated in the cancer cells of all 12 PDAC specimens that we analyzed ([Figure 1A,B](#F1){ref-type="fig"}). In addition, high levels of MSP can be detected in the pancreatic cancer cells disseminated to the liver in all four samples that we were able to obtain ([Figure 1C](#F1){ref-type="fig"}). We also performed IHC staining on a tissue microarray (TMA) that includes 38 PDAC samples and found that high levels of MSP can be detected in 79% (30 of 38) of the specimens ([Table 1](#T1){ref-type="table"}).

![MSP expression is upregulated in Pancreatic ductal adenocarcinoma (PDAC) primary tumors and liver metastasis. Immunohistochemistry (IHC) analysis of human tissues using anti-MSP antibody. **(A)** Normal pancreas; **(B)** PDAC; **(C)** Pancreatic cancer metastasis to the liver. Magnification: 20×; Scale bar: 100 μm.](fphys-10-00147-g001){#F1}

###### 

Macrophage-stimulating protein (MSP) levels in tissue micro array (TMA) of Pancreatic intraepithelial neoplasias (PanIN), and Pancreatic ductal adenocarcinoma (PDAC).

  Tissue type   MSP high   MSP low   *P*-value
  ------------- ---------- --------- -----------
  PanIN         2          12        
  PDAC          30         8         0.0002
                                     

The number of each tissue type with high or low levels of MSP is shown.

We noted that the epithelial cells with morphology of normal or non-transformed ductal cells consistently express little MSP ([Figure 2](#F2){ref-type="fig"}). To determine whether MSP is selectively upregulated during the transition from PanIN to PDAC, we analyzed a TMA that includes fourteen PanIN samples. Interestingly, we found that only 14% (2 of 14) of the PanIN samples were stained MSP positive. These include 0 of 11 specimens that were characterized as PanIN 1/2, and 2 of 3 as PanIN 3 ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Although we were not able to obtain sufficient number of tissues with characteristics of PanIN 3, it appears that upregulation of MSP occurs at either the transition to PanIN3 or PDAC, but not in PanIN 1/2.

![MSP expression in human pancreatic cancer tissues and tissue micro array (TMA). IHC staining of human pancreatic tissues using anti-MSP antibody. **(A)** PDAC. Note that MSP can be detected in cancer cells (arrowheads) but not in normal or un transformed ductal epithelial cells (arrows). **(B)** Representative images of TMA with PanIN1/2 or 3. Magnification: 20×; Scale bar: 100 μm.](fphys-10-00147-g002){#F2}

RON Levels Are Increased in Pancreatic Cancer Cells and in PDAC-Associated Stellate Cells
-----------------------------------------------------------------------------------------

Our IHC staining show that RON expression levels are significantly higher in PDAC, when compared to normal pancreas ([Figure 3](#F3){ref-type="fig"}). Of note, we found that some stromal cells in PDAC were stained positive for RON ([Figure 3](#F3){ref-type="fig"}). These cells show morphology of stellate cells ([Figure 3B](#F3){ref-type="fig"}; indicated by the arrows). These results indicate that RON is present in both cancer cells and in the PDAC-associated stellate cells.

![Recepteur d'Origine Nantais (RON) expression is increased in PDAC. IHC analysis of human pancreatic specimens using anti-RON antibody. **(A)** Normal pancreas; **(B)** PDAC. The arrows indicate RON-positive stellate cells. Magnification: 20×; Scale bar: 100 μm.](fphys-10-00147-g003){#F3}

Upregulation of Matriptase in PDAC
----------------------------------

Because matriptase has been shown to be involved in the processing and maturation of the active form of MSP ([@B7]), we evaluated its expression levels in 12 specimens of normal pancreas and PDAC tissues, respectively. Similar to the expression patterns of MSP, matriptase levels are very low or barely detectable in all normal pancreatic tissues, but can be detected at high levels, notably on the plasma membrane, in the epithelial cells of all PDAC samples that we tested ([Figure 4A](#F4){ref-type="fig"}). Moreover, high levels of matriptase can be detected in the pancreatic cancer cells of all four samples of PDAC liver metastasis that we examined, but not in the hepatic parenchymal cells ([Figure 4B](#F4){ref-type="fig"}). Using a limited number of specimens that show PanIN characteristics, we found that matriptase can be detected in the preneoplastic lesions ([Figure 4A](#F4){ref-type="fig"}; 6 of 7 PanIN1/2; 2 of 2 PanIN3), which indicates that upregulation of matriptase probably occurs earlier than that of MSP.

![Matriptase expression is upregulated in PanIN, primary PDAC and liver metastasis. IHC analysis of normal human pancreatic tissues using anti-matriptase antibody. Representative staining images are shown. **(A)** Normal pancreas, PanIN1/2, PanIN 3, and PDAC; **(B)** Specimen of pancreatic cancer liver metastasis. The areas of the tumor and the adjacent tumor are indicated. Magnification: 4× (left panel) or 20×; Scale bar: 500 (left panel) or 100 μm.](fphys-10-00147-g004){#F4}

MSP Levels Are Elevated in KRAS^G12D^ Mutant-Mediated Pancreatic Intraepithelial Neoplastic Lesion and a Mouse Model of PDAC
----------------------------------------------------------------------------------------------------------------------------

We also examined MSP expression patterns in a transgenic mouse model of pancreatic neoplasm. The KRAS gene is mutated in more than 90% of pancreatic cancer patients ([@B1]; [@B43]). Mutations of KRAS, such as G12D, can lead to abnormal activation of KRAS and are thought to be a driver of early neoplastic lesions ([@B44]). In the Pdx1-Cre/LSL-KRAS^G12D/+^ (KC) transgenic mice, the KRAS^G12D^ mutant is expressed in pancreatic epithelial cells by virtue of the Pdx1 promoter-mediated expression of Cre recombinase and promotes development of PanIN ([@B19]). In addition, co-expression of the p53^R172H^ and KRAS^G12D^ mutants in the pancreas, as in the KPC mice, leads to PDAC ([@B20]). Our IHC studies indicate that, in the control Pdx1-Cre mice, cells in the exocrine pancreas express little, if any, MSP ([Figure 5](#F5){ref-type="fig"}). In contrast, High levels of MSP can be detected in some of cells exhibiting PanIN morphology in the pancreas of the KC mice, and in all PDAC cells in the KPC mice ([Figure 5](#F5){ref-type="fig"}). However, because our antibodies react poorly with mouse matriptase or RON, we were not able to examine these proteins in the KC or KPC mice.

![MSP expression in mouse pancreatic tissues. IHC analysis of mouse pancreatic tissues using anti-MSP antibody. **(A)** control (Pdx1-Cre); **(B)** KC mice (LSL-KRAS^G12D/+^; Pdx1-Cre); or **(C)** KPC mice (LSL-KRAS^G12D/+^; LSL-p53^R172H/+^; Pdx1-Cre). Magnification: 20×; Scale bar: 100 μm.](fphys-10-00147-g005){#F5}

Discussion
==========

In this study, we show that MSP and the protease responsible for its activation, namely matriptase, are upregulated in PDAC primary tumors and liver metastases. Our finding of high levels of RON in PDAC is consistent with previous reports that link aberrant RON expression to pancreatic cancer progression and metastasis ([@B10]; [@B50]; [@B11]). Our analysis of a limited number of samples suggests that upregulation of matriptase occurs prior to that of MSP. Similar to what we found with MSP and matriptase, an increase of RON expression has been noted in the PanIN stage ([@B50]). It would be of interest to expand these studies and characterize further the sequence of events that promote the activation of this signaling pathway and neoplastic transformation. Conceivably, matriptase and MSP, especially its active form, may be explored as a potential biomarker for early detection of PDAC.

The active form of MSP can bind RON, leading to its homo dimerization and activation of various downstream signaling events, such as RAS-MAPK and PI-3 Kinase pathways ([@B31]; [@B51]). In addition, RON can modulate signaling events through forming heterodimers with other receptors such as c-MET ([@B16]; [@B6]), EGFR ([@B40]; [@B49]; [@B29]), the platelet-derived growth factor receptor (PDGFR) ([@B26]), and insulin-like growth factor 1 receptor (IGF1R) ([@B41]; [@B23]). Activation of KRAS signaling has been linked to progression of pancreatic cancer. Indeed, KRAS mutations have been found in more than 90% human PanIN lesions as well as PDACs ([@B1]; [@B48]; [@B25]; [@B36]). Many KRAS coden 12 mutations, such as KRAS^G12D^, can lead to structural alterations that reduce the GTPase activity and prolong the GTP-bound, "active" form for signaling ([@B44]). Notably, the signaling events upstream of KRAS, such as the one initiated from the RTK are required in transformation mediated by KRAS mutants ([@B22]). For example, EGFR is required for KRAS-induced neoplasm ([@B5]; [@B37]). Thus, our findings suggest that the matriptase-MSP-RON signaling axis may represent an autocrine mechanism involved in promoting the transition from PanIN to PDAC by stimulating RTK and KRAS signaling ([Figure 6](#F6){ref-type="fig"}).

![Schematic representation of the mechanism by which the matriptase-MSP-RON signaling axis modulates pancreatic cancer progression. Matriptase mediates maturation and activation of MSP, which in turn stimulates RON-modulated signaling events. It is conceivable that Matriptase and MSP may also contribute to remodeling of the tumor microenvironment, through regulating the functions of the stellate cell, the macrophage, or other immune cells.](fphys-10-00147-g006){#F6}

Similar to what has been found in pancreatic cancer, activation of RON is also associated with tumorigenicity and metastasis of various other forms of human malignancy, such as bladder cancer, head and neck squamous cell carcinomas, breast cancer, ovarian cancer, and colorectal cancer ([@B12]; [@B56]; [@B28]; [@B13]; [@B27]). In particular, MSP has been shown to increase the invasive behavior and resistance to apoptosis in non-small cell lung cancer ([@B54]), as well as bone metastasis in breast cancer ([@B7]; [@B53]). A recent study indicate that MSP-RON can promote metastasis through activation of an MBD4-mediated DNA methylation program ([@B14]). Inhibition of RON can enhance cancer cell sensitivity to chemotherapy drugs such as gemcitabine ([@B30]) or histone deacetylase inhibitors ([@B57]). The MSP-RON signaling network thus represents a potential therapeutic target for treatment of pancreatic cancer. However, it should be noted that because of the cross talk between RON and other RTKs, such as c-MET and erbB family members, a successful therapeutic approach may require simultaneous inhibition of multiple RTKs.

The MSP protein produced by pancreatic cancer cells may also be involved in cancer-stromal cell interaction through a paracrine mechanism. MSP was initially identified as a protein that modulates macrophage activities and RON has been shown to be involved in conversion to the M2-like macrophage ([@B47]; [@B34]; [@B45]). Tumor-associated macrophages show characteristics of the M2-like phenotype and represent a major species of tumor-promoting immune cells in the tumor microenvironment ([@B17]; [@B38]). It would be of interest to determine whether matriptase and the activated forms of MSP proteins produced by cancer cells can modify macrophage behaviors. Alternatively, matriptase and MSP may contribute to shaping an immune suppressive landscape by acting upon other immune cells ([Figure 6](#F6){ref-type="fig"}).

PDAC is characterized by a fibrotic and inflammatory microenvironment that is dominated by activated stellate cells. Our results show high levels of RON expression in the PDAC-associated PSCs. PSCs are myofibroblast like cells that are normally quiescent but become activated in damaged pancreas or the neoplastic niche, and produce collagen, fibronectin and fibrosis promoting growth factors and cytokines ([@B2],[@B3]; [@B15]). Both PDGFR and EGFR are expressed in PSC and involved in its proliferation and functions ([@B4]; [@B8]). It is conceivable that MSP can modulate cancer-stellate cell interaction through activation of RON and the interplay with other RTK signaling events in PSC ([Figure 6](#F6){ref-type="fig"}).

In summary, our study demonstrates that the expression levels of matriptase, MSP and RON are significantly upregulated during the transition from the preneoplastic PanIN stage to the more advanced PDAC and metastatic lesions. These findings support the notion that activation of the matriptase-MSP-RON signaling network may play a critical role in neoplastic transformation in the pancreas.

Materials and Methods {#s1}
=====================

Antibodies
----------

The antibodies used in this study include: anti-MSP/MST1 (ab124787, Abcam, Cambridge, MA; MABF210, EMD Millipore, Burlington, MA, United States); anti-RON/MST1R (C-20, sc-322, Santa Cruz Biotechnology, Santa Cruz, CA, United States; MAB691, R&D Systems, Minneapolis, MN, United States); anti-alpha smooth muscle actin (α-SMA) (A2547, Sigma, St. Louis, MO, United States); anti-matriptase antibodies (\#IM1014, EMD Millipore; D-7, sc-365482, Santa Cruz Biotechnology); HRP-conjugated secondary antibodies against mouse or rabbit were from Dako (Carpinteria, CA, United States).

Human Tissues
-------------

Formalin-fixed and paraffin-embedded (FFPE) human specimens were obtained from the Cedars-Sinai Pathology archive and Biorepository with protocols approved by the Internal Review Board at the Cedars-Sinai Medical Center (IRB protocols \#4201, \#28197, and \#34086). The tissue microarrays were obtained from US Biomax (Rockville, MD, United States).

Transgenic Mice
---------------

All animal procedures were approved by the Cedars-Sinai Institutional Animal Care and Use Committee (IACUC) and performed in accordance with relevant guidelines and regulations (protocols \#3935 and \#8001). The KC and KPC mice derived from the LSL-KRAS^G12D/+^, LSL-p53^R172H/+^, and Pdx1-Cre (KPC) mice were described previously ([@B19], [@B20]). The tissues were collected from 6-month-old mice, fixed in formalin and embedded in paraffin.

Immunohistochemistry
--------------------

Specimens of normal pancreas, PDAC, tissues with characteristics of PanINs, or pancreatic cancer metastasis to the liver, were analyzed. IHC was performed using a previously established protocol ([@B35]). Briefly, the FFPE specimens were de-paraffinized, rehydrated, and subjected to heat induced antigen retrieval. After incubating in animal-free blocker for 30 min (SP-5030, Vector Laboratories, Burlingame, CA, United States), the samples were treated with primary antibody diluted at 1:200 to 1:1000 for 2 h or overnight. The sections were then washed three times in PBS, followed by incubation with secondary antibody for 1--2 h. The samples were washed, and specific stains were developed with the DAB Peroxidase substrate kit (SK4100, Vector Laboratories). The slides were mounted and scanned using Aperio Scanscope^®^AT Turbo (Leica Microsystems, Buffalo Grove, IL, United States). The results were evaluated using a binary scoring system, defined as either undetectable (negative) versus detectable (positive), or low versus high levels of staining. The correlation between gene expression and PDAC stages was examined using chi-squared test (GraphPad Prism, San Diego, CA, United States).
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